Experience with Argon Plasma Coagulation in Treatment of Recurrent Epistaxis in Patients with Hereditary Hemorrhagic Telangiectasia

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064203%3A_____%2F22%3A10444090" target="_blank" >RIV/00064203:_____/22:10444090 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11110/22:10444090

Výsledek na webu

<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=Sx00CroTCb" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=Sx00CroTCb</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.5152/B-ENT.2022.21395" target="_blank" >10.5152/B-ENT.2022.21395</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Experience with Argon Plasma Coagulation in Treatment of Recurrent Epistaxis in Patients with Hereditary Hemorrhagic Telangiectasia

Popis výsledku v původním jazyce

Objective: Hereditary hemorrhagic telangiectasia, or Rendu-Osler-Weber disease, is an autosomal dominant genetic disorder characterized by abnormal vessel formation. Otorhinolaryngologists often struggle with recurrent epistaxis caused by telangiectasias of the nasal mucosa. Many types of local treatments have been reported, including argon plasma coagulation, which is a non-contact electrocoagulation method used widely in surgery. The goal of this retrospective study was to enlist all patients with hereditary hemorrhagic telangiectasia treated with argon plasma coagulation for recurrent epistaxis at our department and to assess our experiences with the method. Methods: This study includes all hereditary hemorrhagic telangiectasia patients treated by argon plasma coagulation at our department starting from 2010, the year when we began using the method, until 2019. Most patients also applied topical estriol ointment in conjunction with the treatment. All patients complained of frequent heavy epistaxis before the surgery and some even required repeated blood transfusions. Results: Thirty-six patients underwent argon plasma coagulation in the monitored period (2010-2019) with mean age 54.75 and median age 59.5 years. All patients had telangiectasias in the nasal cavity. The oral mucosa and skin were also frequently affected, and 2 patients had telangiectasias in other organs. Twenty-two patients had more than 1 procedure, with a maximum of 16. All patients were satisfied with the effect of argon plasma coagulation on the severity and frequency of their epistaxis, and no major complications during or after the surgery were reported. Conclusion: Argon plasma coagulation seems to be a safe, minimally invasive, and effective method in managing recurrent epistaxis in hereditary hemorrhagic telangiectasia patients.

Název v anglickém jazyce

Experience with Argon Plasma Coagulation in Treatment of Recurrent Epistaxis in Patients with Hereditary Hemorrhagic Telangiectasia

Popis výsledku anglicky

Objective: Hereditary hemorrhagic telangiectasia, or Rendu-Osler-Weber disease, is an autosomal dominant genetic disorder characterized by abnormal vessel formation. Otorhinolaryngologists often struggle with recurrent epistaxis caused by telangiectasias of the nasal mucosa. Many types of local treatments have been reported, including argon plasma coagulation, which is a non-contact electrocoagulation method used widely in surgery. The goal of this retrospective study was to enlist all patients with hereditary hemorrhagic telangiectasia treated with argon plasma coagulation for recurrent epistaxis at our department and to assess our experiences with the method. Methods: This study includes all hereditary hemorrhagic telangiectasia patients treated by argon plasma coagulation at our department starting from 2010, the year when we began using the method, until 2019. Most patients also applied topical estriol ointment in conjunction with the treatment. All patients complained of frequent heavy epistaxis before the surgery and some even required repeated blood transfusions. Results: Thirty-six patients underwent argon plasma coagulation in the monitored period (2010-2019) with mean age 54.75 and median age 59.5 years. All patients had telangiectasias in the nasal cavity. The oral mucosa and skin were also frequently affected, and 2 patients had telangiectasias in other organs. Twenty-two patients had more than 1 procedure, with a maximum of 16. All patients were satisfied with the effect of argon plasma coagulation on the severity and frequency of their epistaxis, and no major complications during or after the surgery were reported. Conclusion: Argon plasma coagulation seems to be a safe, minimally invasive, and effective method in managing recurrent epistaxis in hereditary hemorrhagic telangiectasia patients.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30206 - Otorhinolaryngology

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2022

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

B-ENT

ISSN

1781-782X

e-ISSN

—

Svazek periodika

18

Číslo periodika v rámci svazku

2

Stát vydavatele periodika

BE - Belgické království

Počet stran výsledku

6

Strana od-do

85-90

Kód UT WoS článku

000797401700003

EID výsledku v databázi Scopus

2-s2.0-85130140746